drome and hemophagocytosis in mice. Arthritis Rheum 2013;65:1764–75.

7. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, AntonellisKJ, Scherf U, et al. Exploration, normalization, and summaries ofhigh density oligonucleotide array probe level data. Biostatistics2003;4:249–64.

8. Huang DW, Sherman BT, Lempicki RA. Systematic and integra-tive analysis of large gene lists using DAVID bioinformaticsresources. Nat Protoc 2009;4:44–57.

9. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL,Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.Proc Natl Acad Sci U S A 2005;102:15545–50.

10. Coates PJ, Rundle JK, Lorimore SA, Wright EG. Indirect macro-phage responses to ionizing radiation: implications for genotype-dependent bystander signaling. Cancer Res 2008;68:450–6.

11. Schaer CA, Schoedon G, Imhof A, Kurrer MO, Schaer DJ.Constitutive endocytosis of CD163 mediates hemoglobin-hemeuptake and determines the noninflammatory and protective tran-

scriptional response of macrophages to hemoglobin. Circ Res2006;99:943–50.

12. Fall N, Barnes M, Thornton S, Luyrink L, Olson J, Ilowite NT, etal. Gene expression profiling of peripheral blood from patientswith untreated new-onset systemic juvenile idiopathic arthritisreveals molecular heterogeneity that may predict macrophageactivation syndrome. Arthritis Rheum 2007;56:3793–804.

13. Nguyen KD, Macaubas C, Nadeau KC, Truong P, Yoon T, Lee T,et al. Serum amyloid A overrides Treg anergy via monocyte-dependent and Treg-intrinsic, SOCS3-associated pathways. Blood2011;117:3793–8.

14. Chang CH, Curtis JD, Maggi LB Jr, Faubert B, Villarino AV,O’Sullivan D, et al. Posttranscriptional control of T cell effectorfunction by aerobic glycolysis. Cell 2013;153:1239–51.

15. Mukhopadhyay S, Varin A, Chen Y, Liu B, Tryggvason K, GordonS. SR-A/MARCO-mediated ligand delivery enhances intracellularTLR and NLR function, but ligand scavenging from cell surfacelimits TLR4 response to pathogens. Blood 2011;117:1319–28.

Errata

DOI 10.1002/art.38706

In Table 2 of the article by Freed et al in the December 2011 issue of Arthritis & Rheumatism (pages3733–3739), the numbers of rheumatoid arthritis patients and control subjects positive for the resistanceepitope D70 were shown incorrectly. The correct numbers of rheumatoid arthritis patients and controlsubjects, respectively, were 209 and 299.

DOI 10.1002/art.38693

In the article by Kanno et al in the February 2013 issue of Arthritis & Rheumatism (pages 492–502), theconcentration of �2-antiplasmin (�2AP) used in experiments was shown incorrectly in several figures and/orfigure legends. In Figures 1C and E, Figures 2A and B, Figures 4A and B, and Figures 5D and E, the �2APconcentration should have been shown as 2 nM.

DOI 10.1002/art.38707

In the lower panel of Figure 1 of the article by Hanly et al in the November 2013 issue of Arthritis &Rheumatism (pages 2887–2897), the data points for intractable headaches and cluster headaches at theenrollment visit were inadvertently reversed. The correct values are 6.49% for intractable headaches at theenrollment visit and 2.36% for cluster headaches at the enrollment visit. Additionally, in the text of the articlethe prevalence of headache at 10 years was incorrectly stated. The first full sentence on page 2888 shouldhave read, “The prevalence of headache increased to 42% after 10 years” and the last sentence on page2890 (continuing onto page 2891) should have read, “The established proportion of patients who everreported a headache (Kaplan-Meier estimate) increased to 42% after 10 years (Figure 2).”

DOI 10.1002/art.38708

In the article by Golding et al published in the November 2013 issue of Arthritis & Rheumatism (pages2898–2906), acknowledgment of an author’s funding was inadvertently omitted. The paragraph on fundingsupport in the footnotes on the first page of the article should have included the statement, “Dr. Golding’swork was supported by a VA Career Development Award (IK2 CX-000649).”

DOI 10.1002/art.38709

The byline of the Reply letter by Golding et al published in the May 2014 issue of Arthritis & Rheumatology(pages 1403–1404) contained several errors. First, the correct spelling of the second author’s name is EthanM. Shevach, MD. Second, the correct name of the institute where Dr. Hasni is employed is the NationalInstitute of Arthritis and Musculoskeletal and Skin Diseases. Third, Dr. Illei is currently employed byMedImmune, Gaithersburg, MD.

We regret the errors.

ALTERNATIVE ACTIVATION OF MURINE HPCs 1671